MedTrace Logo

Long-term Effects of Medication for ADHD

NCT03250013 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 128

Last updated 2022-03-14

No results posted yet for this study

Summary

Single-centre open-label prospective study, enrolling 127 children and adolescents aged 6-17 years, who receive medication for ADHD of any subtype (presentation). Long-term results are evaluated with tests of ADHD symptoms (Qb-test), intellectual ability (Wechsler scales; WISC), adaptive functioning (Vineland scale), everyday functioning (Weiss Functional Impairment Scale; WFIRS), and quality of life (Child Health and Illness Profile-Child Edition Scale; CHIP-CE) during 24 months of ADHD treatment.

Conditions

  • Attention Deficit Disorder With Hyperactivity

Interventions

DRUG

ADHD medications

Sponsors & Collaborators

  • Göteborg University

    lead OTHER

Principal Investigators

  • Mats Johnson, MD, PhD · Child Neuropsychiatry Unit, Sahlgrenska University Hospital, Gothenburg, Sweden

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
6 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-04-30
Primary Completion
2022-01-30
Completion
2022-01-30

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03250013 on ClinicalTrials.gov